BCTXW

BCTXW

BriaCell Therapeutics Corp. Warrant

$0.089+0.000 (0.000%)

Echtzeitkurs

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen
Unternehmensfundamentaldaten
Handelsstatistiken

Marktkennzahlen

Eröffnung

$0.000

Hoch

$0.000

Tief

$0.000

Volumen

0.02M

Unternehmensfundamentaldaten

Handelsstatistiken

Ähnliche Nachrichten

GlobeNewswire

BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26

PHILADELPHIA and VANCOUVER, British Columbia, June 04, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ)), (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company

Mehr anzeigen
BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26
GlobeNewswire

BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025

Three BriaCell posters and one publish-only abstract highlight robust clinical data from Bria-IMT™ and Bria-OTS™ studies in metastatic breast cancer (MBC)Median Overall Survival of 17.3 months in Phase 2

Mehr anzeigen
BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025
GlobeNewswire

BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor

Bria-OTS has cleared its safety evaluation in the Phase 1/2 study monotherapy dosage settingPhase 1/2 study has now transitioned to dosing patients in combination with checkpoint inhibitor in metastatic breast cancer

Mehr anzeigen
BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor
GlobeNewswire

BriaCell CEO Letter to Shareholders

Repeated positive recommendation from Data Safety Monitoring Board ("DSMB") of pivotal Phase 3 study for lead clinical candidate Bria-IMT™ in combination with checkpoint inhibitorBria-IMT has received Fast Track

Mehr anzeigen
BriaCell CEO Letter to Shareholders